Michael Ahdoot1, Amir H Lebastchi1, Baris Turkbey2, Bradford Wood3, Peter A Pinto1. 1. Urologic Oncology Branch (UOB), National Cancer Institute (NCI). 2. Molecular Imaging Program, Center for Cancer Research, National Institute of Health. 3. Center for Interventional Oncology, National Cancer Institute, & Interventional Radiology, Radiology and Imaging Sciences, NIH Clinical Center, Bethesda, Maryland, USA.
Abstract
PURPOSE OF REVIEW: Radical treatments for prostate cancer are associated with significant morbidity, including incontinence and erectile dysfunction. Advances in the field of prostate MRI and desire to reduce treatment morbidities have led to a rapid growth in focal treatments for prostate cancer. Here, we review novel focal prostate cancer treatments and their associated recent clinical data, with a particular focus on data reported within the last 24 months. RECENT FINDINGS: High-intensity focal ultrasound, focal laser ablation, irreversible electroporation, focal cryotherapy, and photodynamic therapy have been used as treatment modalities for localized prostate cancer treatment. Despite the great variety of treatment techniques, each of these modalities is characterized by a significant rate of prostate cancer persistence within treatment zones (6-50%) and the presence of residual cancer within the prostate on rebiopsy (24-49%). These treatments, however, are associated with very low rates of high-grade complications, rare incontinence, and only mild or transient reductions in erectile function. The most common adverse events are urinary tract infections, hematuria, and urinary retention. SUMMARY: Prostate cancer focal therapy is an attractive option for well-selected patients because of its low complication profile; however, long-term oncologic outcome is still lacking and early recurrence rates are high, limiting the ability of most urologic associations from endorsing its routine use.
PURPOSE OF REVIEW: Radical treatments for prostate cancer are associated with significant morbidity, including incontinence and erectile dysfunction. Advances in the field of prostate MRI and desire to reduce treatment morbidities have led to a rapid growth in focal treatments for prostate cancer. Here, we review novel focal prostate cancer treatments and their associated recent clinical data, with a particular focus on data reported within the last 24 months. RECENT FINDINGS: High-intensity focal ultrasound, focal laser ablation, irreversible electroporation, focal cryotherapy, and photodynamic therapy have been used as treatment modalities for localized prostate cancer treatment. Despite the great variety of treatment techniques, each of these modalities is characterized by a significant rate of prostate cancer persistence within treatment zones (6-50%) and the presence of residual cancer within the prostate on rebiopsy (24-49%). These treatments, however, are associated with very low rates of high-grade complications, rare incontinence, and only mild or transient reductions in erectile function. The most common adverse events are urinary tract infections, hematuria, and urinary retention. SUMMARY:Prostate cancer focal therapy is an attractive option for well-selected patients because of its low complication profile; however, long-term oncologic outcome is still lacking and early recurrence rates are high, limiting the ability of most urologic associations from endorsing its routine use.
Authors: R Jason Stafford; Anil Shetty; Andrew M Elliott; Sherry A Klumpp; Roger J McNichols; Ashok Gowda; John D Hazle; John F Ward Journal: J Urol Date: 2010-08-19 Impact factor: 7.450
Authors: Jost von Hardenberg; Niklas Westhoff; Daniel Baumunk; Daniel Hausmann; Thomas Martini; Alexander Marx; Stefan Porubsky; Martin Schostak; Maurice Stephan Michel; Manuel Ritter Journal: Urol Oncol Date: 2018-08-06 Impact factor: 3.498
Authors: Henk G van der Poel; Roderick C N van den Bergh; Erik Briers; Philip Cornford; Alex Govorov; Ann M Henry; Thomas B Lam; Malcolm D Mason; Olivier Rouvière; Maria De Santis; Peter-Paul M Willemse; Hendrik van Poppel; Nicolas Mottet Journal: Eur Urol Date: 2018-01-17 Impact factor: 20.096
Authors: Samuel Borofsky; Arvin K George; Sonia Gaur; Marcelino Bernardo; Matthew D Greer; Francesca V Mertan; Myles Taffel; Vanesa Moreno; Maria J Merino; Bradford J Wood; Peter A Pinto; Peter L Choyke; Baris Turkbey Journal: Radiology Date: 2017-10-20 Impact factor: 11.105
Authors: Sangeet Ghai; Nathan Perlis; Uri Lindner; Eugen Hlasny; Masoom A Haider; Antonio Finelli; Alexandre R Zlotta; Girish S Kulkarni; Theodorus H van der Kwast; Stuart A McCluskey; Walter Kucharczyk; John Trachtenberg Journal: Eur Radiol Date: 2018-04-25 Impact factor: 5.315
Authors: Pieter J L De Visschere; Alberto Briganti; Jurgen J Fütterer; Pirus Ghadjar; Hendrik Isbarn; Christophe Massard; Piet Ost; Prasanna Sooriakumaran; Cristian I Surcel; Massimo Valerio; Roderick C N van den Bergh; Guillaume Ploussard; Gianluca Giannarini; Geert M Villeirs Journal: Insights Imaging Date: 2016-02-04
Authors: Amin Ali; Alexander Du Feu; Pedro Oliveira; Ananya Choudhury; Robert G Bristow; Esther Baena Journal: Nat Rev Urol Date: 2021-10-19 Impact factor: 14.432
Authors: Rory Geoghegan; Le Zhang; Alan Priester; Holden H Wu; Leonard Marks; Shyam Natarajan Journal: IEEE Trans Biomed Eng Date: 2022-07-18 Impact factor: 4.756
Authors: Soleen Ghafoor; Daniel Stocker; Olivio F Donati; Hebert Alberto Vargas; Anton S Becker; Borna K Barth; Daniel Eberli Journal: Abdom Radiol (NY) Date: 2020-11
Authors: Wei Phin Tan; Ardeshir R Rastinehad; Laurence Klotz; Peter R Carroll; Mark Emberton; John F Feller; Arvin K George; Inderbir S Gill; Rajan T Gupta; Aaron E Katz; Amir H Lebastchi; Leonard S Marks; Giancarlo Marra; Peter A Pinto; Daniel Y Song; Abhinav Sidana; John F Ward; Rafael Sanchez-Salas; Jean de la Rosette; Thomas J Polascik Journal: Urol Oncol Date: 2021-03-04 Impact factor: 3.498
Authors: Amir H Lebastchi; Arvin K George; Thomas J Polascik; Jonathan Coleman; Jean de la Rosette; Baris Turkbey; Bradford J Wood; Michael A Gorin; Abhinav Sidana; Sangeet Ghai; Kae Jack Tay; John F Ward; Rafael Sanchez-Salas; Berrend G Muller; Bernard Malavaud; Pierre Mozer; Sebastien Crouzet; Peter L Choyke; Osamu Ukimura; Ardeshir R Rastinehad; Peter A Pinto Journal: Eur Urol Date: 2020-06-10 Impact factor: 20.096